SION vs TENX
SION: Sionna Therapeutics is a clinical-stage biopharma company pioneering NBD1-stabilizing therapies to treat the underlying cause of cystic fibrosis. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | SION | TENX | Edge |
|---|---|---|---|
| Price as of 2026-09-04 close | $7.18 | $1.94 | |
| Market cap as of 2026-09-02 | $325M | $51M | |
| PEG as of 2026-09-02 | -0.11 | -0.02 | SION lower |
| ROE FY2025, SEC XBRL | -24.5% | -54.2% | SION higher |
| ROA FY2025, SEC XBRL | -23.1% | -50.5% | SION higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -82.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.93 | 0.47 | |
| 1-year return as of 2026-09-04 close | -68.9% | -67.7% | TENX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.